Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.

Reznichenko O, Quillévéré A, Martins RP, Loaëc N, Kang H, Lista MJ, Beauvineau C, González-García J, Guillot R, Voisset C, Daskalogianni C, Fåhraeus R, Teulade-Fichou MP, Blondel M, Granzhan A.

Eur J Med Chem. 2019 Sep 15;178:13-29. doi: 10.1016/j.ejmech.2019.05.042. Epub 2019 May 23.

PMID:
31173968
2.

Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy.

Malerba A, Roth F, Harish P, Dhiab J, Lu-Nguyen N, Cappellari O, Jarmin S, Mahoudeau A, Ythier V, Lainé J, Negroni E, Abgueguen E, Simonelig M, Guedat P, Mouly V, Butler-Browne G, Voisset C, Dickson G, Trollet C.

Hum Mol Genet. 2019 May 15;28(10):1694-1708. doi: 10.1093/hmg/ddz007.

PMID:
30649389
3.

p53, p63 and p73 in the wonderland of S. cerevisiae.

Billant O, Blondel M, Voisset C.

Oncotarget. 2017 Jun 16;8(34):57855-57869. doi: 10.18632/oncotarget.18506. eCollection 2017 Aug 22. Review.

4.

A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness.

Lista MJ, Martins RP, Angrand G, Quillévéré A, Daskalogianni C, Voisset C, Teulade-Fichou MP, Fåhraeus R, Blondel M.

Microb Cell. 2017 Aug 31;4(9):305-307. doi: 10.15698/mic2017.09.590.

5.

Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.

Lista MJ, Martins RP, Billant O, Contesse MA, Findakly S, Pochard P, Daskalogianni C, Beauvineau C, Guetta C, Jamin C, Teulade-Fichou MP, Fåhraeus R, Voisset C, Blondel M.

Nat Commun. 2017 Jul 7;8:16043. doi: 10.1038/ncomms16043.

6.

The double life of the ribosome: When its protein folding activity supports prion propagation.

Voisset C, Blondel M, Jones GW, Friocourt G, Stahl G, Chédin S, Béringue V, Gillet R.

Prion. 2017 Mar 4;11(2):89-97. doi: 10.1080/19336896.2017.1303587. Review.

7.

Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation.

Blondel M, Soubigou F, Evrard J, Nguyen PH, Hasin N, Chédin S, Gillet R, Contesse MA, Friocourt G, Stahl G, Jones GW, Voisset C.

Sci Rep. 2016 Sep 16;6:32117. doi: 10.1038/srep32117.

8.

The dominant-negative interplay between p53, p63 and p73: A family affair.

Billant O, Léon A, Le Guellec S, Friocourt G, Blondel M, Voisset C.

Oncotarget. 2016 Oct 25;7(43):69549-69564. doi: 10.18632/oncotarget.11774.

9.

The long-lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein-Barr virus.

Lista MJ, Voisset C, Contesse MA, Friocourt G, Daskalogianni C, Bihel F, Fåhraeus R, Blondel M.

Biotechnol J. 2015 Sep;10(11):1670-81. doi: 10.1002/biot.201500161. Epub 2015 Aug 27. Review.

PMID:
26311489
10.

[Chemobiology at happy hour: yeast as a model for pharmacological screening].

Voisset C, Blondel M.

Med Sci (Paris). 2014 Dec;30(12):1161-8. doi: 10.1051/medsci/20143012020. Epub 2014 Dec 24. Review. French.

11.

Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders.

Aiyar RS, Bohnert M, Duvezin-Caubet S, Voisset C, Gagneur J, Fritsch ES, Couplan E, von der Malsburg K, Funaya C, Soubigou F, Courtin F, Suresh S, Kucharczyk R, Evrard J, Antony C, St Onge RP, Blondel M, di Rago JP, van der Laan M, Steinmetz LM.

Nat Commun. 2014 Dec 18;5:5585. doi: 10.1038/ncomms6585.

12.

Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity.

Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Beringue V, Blondel M, Bihel F, Voisset C.

ACS Chem Neurosci. 2014 Oct 15;5(10):1075-82. doi: 10.1021/cn5001588. Epub 2014 Sep 22.

PMID:
25244284
13.

Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.

Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, Nylander K, Voisset C, Blondel M, Fåhraeus R.

J Pathol. 2015 Jan;235(2):334-41. doi: 10.1002/path.4431. Review.

PMID:
25186125
14.

Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles.

Nguyen P, Oumata N, Soubigou F, Evrard J, Desban N, Lemoine P, Bouaziz S, Blondel M, Voisset C.

Eur J Med Chem. 2014 Jul 23;82:363-71. doi: 10.1016/j.ejmech.2014.05.083. Epub 2014 Jun 3.

PMID:
24927056
15.

Using yeast to model calcium-related diseases: example of the Hailey-Hailey disease.

Voisset C, García-Rodríguez N, Birkmire A, Blondel M, Wellinger RE.

Biochim Biophys Acta. 2014 Oct;1843(10):2315-21. doi: 10.1016/j.bbamcr.2014.02.011. Epub 2014 Feb 25. Review.

16.

A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.

Voisset C, Daskalogianni C, Contesse MA, Mazars A, Arbach H, Le Cann M, Soubigou F, Apcher S, Fåhraeus R, Blondel M.

Dis Model Mech. 2014 Apr;7(4):435-44. doi: 10.1242/dmm.014308. Epub 2014 Feb 20.

17.

The toll-like receptor agonist imiquimod is active against prions.

Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C.

PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013.

18.

The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition.

Pang Y, Kurella S, Voisset C, Samanta D, Banerjee D, Schabe A, Das Gupta C, Galons H, Blondel M, Sanyal S.

J Biol Chem. 2013 Jun 28;288(26):19081-9. doi: 10.1074/jbc.M113.466748. Epub 2013 May 14.

19.

The various facets of the protein-folding activity of the ribosome.

Voisset C, Saupe SJ, Blondel M.

Biotechnol J. 2011 Jun;6(6):668-73. doi: 10.1002/biot.201100021. Epub 2011 May 12. Review.

PMID:
21567961
20.

Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding.

Reis SD, Pang Y, Vishnu N, Voisset C, Galons H, Blondel M, Sanyal S.

Biochimie. 2011 Jun;93(6):1047-54. doi: 10.1016/j.biochi.2011.03.002. Epub 2011 Mar 17.

PMID:
21396977
21.

Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, Blondel M, Schwarz E, Simonelig M.

EMBO Mol Med. 2011 Jan;3(1):35-49. doi: 10.1002/emmm.201000109.

22.

Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography.

Gug F, Oumata N, Tribouillard-Tanvier D, Voisset C, Desban N, Bach S, Blondel M, Galons H.

Bioconjug Chem. 2010 Feb 17;21(2):279-88. doi: 10.1021/bc900314n.

PMID:
20092293
23.
24.

Tools for the study of ribosome-borne protein folding activity.

Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M.

Biotechnol J. 2008 Aug;3(8):1033-40. doi: 10.1002/biot.200800134. Review.

PMID:
18683165
25.

Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs.

Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Béringue V, Sabate R, Kikovska E, Talarek N, Bach S, Huang C, Desban N, Saupe SJ, Supattapone S, Thuret JY, Chédin S, Vilette D, Galons H, Sanyal S, Blondel M.

PLoS One. 2008 May 14;3(5):e2174. doi: 10.1371/journal.pone.0002174.

26.

Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M.

PLoS One. 2008 Apr 23;3(4):e1981. doi: 10.1371/journal.pone.0001981.

27.

Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease.

Voisset C, Weiss RA, Griffiths DJ.

Microbiol Mol Biol Rev. 2008 Mar;72(1):157-96, table of contents. doi: 10.1128/MMBR.00033-07. Review.

28.

Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.

Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J.

Cell Microbiol. 2008 Mar;10(3):606-17. Epub 2007 Nov 2.

PMID:
17979982
29.

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16269-74. Epub 2007 Oct 2.

30.

The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.

Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C.

J Virol. 2007 Aug;81(15):8101-11. Epub 2007 May 23.

31.

Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.

Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J.

Hepatology. 2006 Dec;44(6):1626-34.

PMID:
17133472
32.

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.

Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J.

J Gen Virol. 2006 Sep;87(Pt 9):2577-81.

PMID:
16894196
33.

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.

Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J.

J Biol Chem. 2006 Sep 1;281(35):25177-83. Epub 2006 Jun 29.

34.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

35.

Hepatitis C virus entry: potential receptors and their biological functions.

Cocquerel L, Voisset C, Dubuisson J.

J Gen Virol. 2006 May;87(Pt 5):1075-84. Review.

PMID:
16603507
36.

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.

Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J.

J Virol. 2006 Mar;80(6):2832-41.

37.

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL.

Hepatology. 2005 Feb;41(2):265-74.

PMID:
15660396
38.

High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N.

J Biol Chem. 2005 Mar 4;280(9):7793-9. Epub 2005 Jan 4.

39.

Functional hepatitis C virus envelope glycoproteins.

Voisset C, Dubuisson J.

Biol Cell. 2004 Aug;96(6):413-20. Review.

PMID:
15325070
40.

Characterization of functional hepatitis C virus envelope glycoproteins.

Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J.

J Virol. 2004 Mar;78(6):2994-3002.

41.

Rabbit endogenous retrovirus-H encodes a functional protease.

Voisset C, Myers RE, Carne A, Kellam P, Griffiths DJ.

J Gen Virol. 2003 Jan;84(Pt 1):215-25.

PMID:
12533718
42.

Novel endogenous retrovirus in rabbits previously reported as human retrovirus 5.

Griffiths DJ, Voisset C, Venables PJ, Weiss RA.

J Virol. 2002 Jul;76(14):7094-102.

43.
44.

RNA amplification technique, NASBA, also amplifies homologous plasmid DNA in non-denaturing conditions.

Voisset C, Mandrand B, Paranhos-Baccalà G.

Biotechniques. 2000 Aug;29(2):236-8, 240. No abstract available.

45.

Chromosomal distribution and coding capacity of the human endogenous retrovirus HERV-W family.

Voisset C, Bouton O, Bedin F, Duret L, Mandrand B, Mallet F, Paranhos-Baccala G.

AIDS Res Hum Retroviruses. 2000 May 20;16(8):731-40.

PMID:
10826480
46.

Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates.

Voisset C, Blancher A, Perron H, Mandrand B, Mallet F, Paranhos-Baccalà G.

AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1529-33.

PMID:
10580403
47.

Hydrophilic and cationic latex particles for the specific extraction of nucleic acids.

Elaissari A, Holt L, Meunier F, Voisset C, Pichot C, Mandrand B, Mabilat C.

J Biomater Sci Polym Ed. 1999;10(4):403-20.

PMID:
10227464
48.

Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis.

Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7583-8.

Supplemental Content

Loading ...
Support Center